Bristol Competitors

BMY Stock  USD 53.25  0.70  1.33%   
Bristol-Myers Squibb competes with Agilent Technologies, Mustang Bio, Moleculin Biotech, Seres Therapeutics, and Madrigal Pharmaceuticals; as well as few others. The company runs under Pharmaceuticals sector within Health Care industry. Analyzing Bristol Myers competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Bristol Myers to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Bristol Myers Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Bristol Myers competition on your existing holdings.
  
Return On Capital Employed is likely to rise to 0.29 in 2024. Return On Assets is likely to rise to 0.14 in 2024. At this time, Bristol Myers' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 66.6 B in 2024, whereas Other Assets are likely to drop slightly above 3.3 B in 2024.
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Bristol Myers' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
52.0853.2554.42
Details
Intrinsic
Valuation
LowRealHigh
51.0552.2253.39
Details
Naive
Forecast
LowNextHigh
50.8752.0453.21
Details
26 Analysts
Consensus
LowTargetHigh
65.1371.5779.44
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Bristol Myers. Your research has to be compared to or analyzed against Bristol Myers' peers to derive any actionable benefits. When done correctly, Bristol Myers' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Bristol-Myers Squibb.

Bristol Myers Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Bristol Myers and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Bristol and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Bristol-Myers Squibb does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
MEKA
MEMCRB
KAMCRB
MCRBMBIO
MDGLA
MCRBMBRX
  
High negative correlations   

Risk-Adjusted Indicators

There is a big difference between Bristol Stock performing well and Bristol Myers Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Bristol Myers' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

Cross Equities Net Income Analysis

Compare Bristol-Myers Squibb and related stocks such as Agilent Technologies, Mustang Bio, and Moleculin Biotech Net Income Over Time
Select Fundamental
201020112012201320142015201620172018201920202021202220232024
A257 M1.2 B724 M497 M398 M460 M684 M316 M1.1 B719 M1.2 B1.3 B1.2 B1.4 B1.5 B
MBIO(5.4 M)(5.4 M)(5.4 M)(5.4 M)(5.4 M)(5.4 M)(12.7 M)(31.3 M)(30.7 M)(48.2 M)(62.1 M)(64.1 M)(78.9 M)(51.6 M)(54.2 M)
MBRX(365.8 K)(365.8 K)(365.8 K)(365.8 K)(365.8 K)(365.8 K)(3.9 M)(9.8 M)(11.9 M)(13.2 M)(15 M)(8.9 M)(27.4 M)(29.8 M)(28.3 M)
CLVRW(48.1 M)(48.1 M)(48.1 M)(48.1 M)(48.1 M)(48.1 M)(48.1 M)(48.1 M)(48.1 M)(48.1 M)(41.4 M)(45.6 M)(66.1 M)(41.6 M)(43.7 M)
MCRB(3.1 M)(3.1 M)(3.1 M)(6.1 M)(16.7 M)(54.8 M)(91.6 M)(89.4 M)(98.9 M)(64.2 M)(86.5 M)(61.5 M)(253.8 M)(113.7 M)(119.4 M)
MDGL(381 K)(47.4 M)(62.8 M)(90.2 M)(86.2 M)(68.7 M)(26.4 M)(31.2 M)(32.8 M)(72.8 M)(197.4 M)(241.1 M)(299.3 M)(373.6 M)(354.9 M)
EQ(2.3 M)(2.3 M)(2.3 M)(2.3 M)(2.3 M)(2.3 M)(2.3 M)(2.3 M)(13.2 M)(25.6 M)(29.8 M)(39 M)(107.7 M)(13.3 M)(14 M)
KA(59.1 M)(59.1 M)(59.1 M)(59.1 M)(59.1 M)(59.1 M)(59.1 M)(59.1 M)(59.1 M)(59.1 M)(13.9 M)(12 M)(63.1 M)(14.1 M)(14.8 M)
ME(183.5 M)(183.5 M)(183.5 M)(183.5 M)(183.5 M)(183.5 M)(183.5 M)(183.5 M)(183.5 M)(289.3 M)(183.4 M)(217.5 M)(311.7 M)(280.5 M)(294.5 M)

Bristol-Myers Squibb and related stocks such as Agilent Technologies, Mustang Bio, and Moleculin Biotech Net Income description

Net income is one of the most important fundamental items in finance. It plays a large role in Bristol-Myers Squibb financial statement analysis. It represents the amount of money remaining after all of Bristol Myers Squibb operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Bristol Myers Competitive Analysis

The better you understand Bristol Myers competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Bristol Myers' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Bristol Myers' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
BMYAMBIOMBRXCLVRWMCRBMDGLEQKAME
 1.33 
 53.25 
Bristol
 2.05 
 147.37 
Agilent
 1.08 
 0.94 
Mustang
 18.38 
 5.54 
Moleculin
 2.94 
 0.04 
Clever
 4.00 
 0.78 
Seres
 4.52 
 258.81 
Madrigal
 15.57 
 2.06 
Equillium
 5.45 
 0.52 
Kineta
 4.08 
 0.51 
23Andme
Market Volatility
(90 Days Market Risk)
Market Performance
(90 Days Performance)
Odds of Financial Distress
(Probability Of Bankruptcy)
Current Valuation
(Equity Enterprise Value)
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Current Ratio
Net Asset
Profit Margin
EBITDA
Operating Margin
Current Valuation
Price To Book
Retained Earnings
Current Asset
Five Year Return
Beta
Number Of Employees
Shares Outstanding
Cash Flow From Operations
Annual Yield
Total Debt
Return On Equity
Z Score
Return On Asset
Number Of Shares Shorted
Book Value Per Share
Current Liabilities
Total Asset
Debt To Equity
Short Ratio
Target Price
Last Dividend Paid
Shares Owned By Institutions
Market Capitalization
Price To Earning
Price To Earnings To Growth
Price To Sales
Net Income
Earnings Per Share
Shares Owned By Insiders
Revenue
Working Capital
Cash And Equivalents
Cash Per Share
Gross Profit
Day Typical Price
Accumulation Distribution
Daily Balance Of Power
Period Momentum Indicator
Rate Of Daily Change
Day Median Price
Price Action Indicator
Relative Strength Index
Coefficient Of Variation
Mean Deviation
Jensen Alpha
Total Risk Alpha
Sortino Ratio
Downside Variance
Standard Deviation
Kurtosis
Potential Upside
Treynor Ratio
Maximum Drawdown
Variance
Market Risk Adjusted Performance
Risk Adjusted Performance
Skewness
Semi Deviation
Information Ratio
Value At Risk
Expected Short fall
Downside Deviation
Semi Variance

Bristol Myers Competition Performance Charts

Five steps to successful analysis of Bristol Myers Competition

Bristol Myers' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Bristol-Myers Squibb in relation to its competition. Bristol Myers' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Bristol Myers in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Bristol Myers' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Bristol-Myers Squibb, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Bristol Myers position

In addition to having Bristol Myers in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Precious Metals Funds Thematic Idea Now

Precious Metals Funds
Precious Metals Funds Theme
Funds or Etfs that invest in entities that are involved in mining, processing or dealing of precious metals. The Precious Metals Funds theme has 33 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Precious Metals Funds Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Bristol-Myers Squibb offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bristol Myers' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bristol Myers Squibb Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bristol Myers Squibb Stock:
Check out Bristol Myers Correlation with its peers.
You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.

Complementary Tools for Bristol Stock analysis

When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Stocks Directory
Find actively traded stocks across global markets
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Equity Valuation
Check real value of public entities based on technical and fundamental data
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Is Bristol Myers' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bristol Myers. If investors know Bristol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bristol Myers listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.09)
Dividend Share
2.31
Earnings Share
3.86
Revenue Per Share
21.753
Quarterly Revenue Growth
0.006
The market value of Bristol-Myers Squibb is measured differently than its book value, which is the value of Bristol that is recorded on the company's balance sheet. Investors also form their own opinion of Bristol Myers' value that differs from its market value or its book value, called intrinsic value, which is Bristol Myers' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bristol Myers' market value can be influenced by many factors that don't directly affect Bristol Myers' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bristol Myers' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bristol Myers is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bristol Myers' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.